Back to Search
Start Over
Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study
- Source :
- e0242917, PloS one, United States, PLoS ONE, PLoS ONE, Vol 15, Iss 11, p e0242917 (2020)
- Publication Year :
- 2020
- Publisher :
- PLOS, 2020.
-
Abstract
- BackgroundThe viral load and tissue distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain important questions. The current study investigated SARS-CoV-2 viral load, biodistribution and anti-SARS-CoV-2 antibody formation in patients suffering from severe corona virus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS).MethodsThis is a retrospective single-center study in 23 patients with COVID-19-induced ARDS. Data were collected within routine intensive care. SARS-CoV-2 viral load was assessed via reverse transcription quantitative polymerase chain reaction (RT-qPCR). Overall, 478 virology samples were taken. Anti-SARS-CoV-2-Spike-receptor binding domain (RBD) antibody detection of blood samples was performed with an enzyme-linked immunosorbent assay.ResultsMost patients (91%) suffered from severe ARDS during ICU treatment with a 30-day mortality of 30%. None of the patients received antiviral treatment. Tracheal aspirates tested positive for SARS-CoV-2 in 100% of the cases, oropharyngeal swabs only in 77%. Blood samples were positive in 26% of the patients. No difference of viral load was found in tracheal or blood samples with regard to 30-day survival or disease severity. SARS-CoV-2 was never found in dialysate. Serologic testing revealed significantly lower concentrations of SARS-CoV-2 neutralizing IgM and IgA antibodies in survivors compared to non-survivors (p = 0.009).ConclusionsCOVID-19 induced ARDS is accompanied by a high viral load of SARS-CoV-2 in tracheal aspirates, which remained detectable in the majority throughout intensive care treatment. Remarkably, SARS-CoV-2 RNA was never detected in dialysate even in patients with RNAemia. Viral load or the buildup of neutralizing antibodies was not associated with 30-day survival or disease severity.
- Subjects :
- RNA viruses
Male
Viral Diseases
Coronaviruses
Physiology
viruses
Antibodies, Viral
Biochemistry
Medical Conditions
Immune Physiology
Germany
Public and Occupational Health
Enzyme-Linked Immunoassays
Pathology and laboratory medicine
Virus Testing
Respiratory Distress Syndrome
Immune System Proteins
Reverse Transcriptase Polymerase Chain Reaction
Medical microbiology
Viral Load
Middle Aged
Vaccination and Immunization
Hospitals
Intensive Care Units
Infectious Diseases
Viruses
Spike Glycoprotein, Coronavirus
Medicine
RNA, Viral
Female
SARS CoV 2
Pathogens
Research Article
SARS coronavirus
Science
Immunology
Enzyme-Linked Immunosorbent Assay
Research and Analysis Methods
Microbiology
Antibodies
COVID-19 Serological Testing
Antiviral Therapy
Protein Domains
Diagnostic Medicine
Virology
Humans
ddc:610
Immunoassays
Aged
Retrospective Studies
Medicine and health sciences
Biology and life sciences
SARS-CoV-2
Organisms
Viral pathogens
Proteins
COVID-19
Covid 19
Antibodies, Neutralizing
Microbial pathogens
Immunoglobulin A
Health Care
Immunoglobulin M
Health Care Facilities
Immunoglobulin G
Immunologic Techniques
Preventive Medicine
Viral Transmission and Infection
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- e0242917, PloS one, United States, PLoS ONE, PLoS ONE, Vol 15, Iss 11, p e0242917 (2020)
- Accession number :
- edsair.pmid.dedup....1a51d589e86ca2e4334fc4c4f3e81bd9